Osamu Yokosuka

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle et al. · The Lancet · 2016 · 3.7K citations · Full text

Medicine, Oncology, Pharmacology +8

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014

Shiv Kumar Sarin, Chandan Kumar Kedarisetty, Zaigham Abbas et al. · Hepatology International · 2014 · 1.5K citations · Full text

Medicine, Internal Medicine, Gastroenterology +12

Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan

Haruhiko Yoshida, Yasushi Shiratori, Mitsuhiko Moriyama et al. · Annals of Internal Medicine · 1999 · 1.1K citations

Medicine, Oncology, Cancer Control +16

Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy

Yasushi Shiratori, Fumio Imazeki, Mitsuhiko Moriyama et al. · Annals of Internal Medicine · 2000 · 737 citations · Full text

Medicine, Pathology, Hepatology +16

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda et al. · Gut · 2019 · 723 citations · Full text

Medicine, Oncology, Pharmacotherapy +17